PMLive

Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

Novo Nordisk has reported that its 2.4mg dosage of semaglutide (Wegovy) demonstrated a reduction in liver injury ...
PMLive

AstraZeneca reports positive results from rare disease trial

AstraZeneca has reported positive full results from its phase 3 NATRON trial evaluating Fasenra (benralizumab) for the ...
PMLive

Amgen reports positive results from landmark cardiovascular study

Amgen has reported positive results from its phase 3 VESALIUS-CV trial, which demonstrated that Repatha (evolocumab) ...